Higher drug prices will boost development of personalised medicine, says new reportBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4549 (Published 16 July 2013) Cite this as: BMJ 2013;347:f4549
- Krishna Chinthapalli
Raising prices of drugs when they are used for certain indications or in particular groups of patients should be encouraged so that new personalised drugs can be developed, a new report has concluded.1
John Bell, regius professor of medicine at the University of Oxford and chairman of the report’s oversight committee, said, “Current pricing and reimbursement systems do not provide adequate incentives for the development of personalised medicines.
“A new system of pricing needs to be developed that enables prices to be adjusted over time to reflect the increases in value.”
The report, published by the Academy of Medical Sciences, a professional body for biomedical researchers, suggests that the value of a drug could be measured by the National Institute for Care and Excellence (NICE) in terms of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial